Letzte Aktualisierung: 05.04.2023

Primärtherapie AML

AMLSG 23-14

Aktive Studien

Studieninformationen

Eine Phase Ib/IIa Studie zur Therapie mit Palbociclib bei Patienten mit akuter Leukämie und einer Veränderung im MLL-Gen

Behandlungszentren im CIO

Bonn


Düsseldorf


Ziele

Primäres Prüfziel

Phase Ib: - Evaluation des Sicherheitsprofils von Palbociclib - Evaluation der Verträglichkeit von Palbociclib

Phase IIa: - Evaluation der Wirksamkeit von Palbociclib in Form des Behandlungsansprechens (CR, CRi, PR & ALE)

Sekundäre Prüfziele für die Behandlungsarme:

- Bewertung des Rezidiv-freien Überlebens und Gesamtüberlebens

- Inhibition von CDK6 durch Palbociclib

- Beurteilung der Lebensqualität


Design

Phase

Phase I/II

Zentren

Multizentrisch

Datenerhebung

Prospektiv

Interventionsgruppen

Einarmig

Verblindung

Open Label

Erkrankung

Diagnose

Akute myeloische Leukämien (AML)

Diagnosenbeschreibung

Mutation

Stadium

mit Veränderung im MLL-Gen

Patienten

Alter

18 - 99 Jahre

Einschlusskriterien

  • Patients with confirmed diagnosis of acute leukemia with MLL rearrangement according to the 2008 WHO Classification
  • Patients with MLL-rearranged leukemia who are refractory to standard induction therapy and not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
  • Patients with MLL-rearranged leukemia who relapsed after standard first-line treatment and are not immediate candidates for allogeneic HSCT (bridge to transplant is allowed)
  • Patients with newly diagnosed MLL-rearranged leukemia who are not eligible for intensive first-line therapy
  • Genetic assessment in the AMLSG central laboratory
  • Age ≥ 18 years, no upper age limit
  • WHO performance status of ≤ 2
  • No prior chemotherapy two weeks before study entry except hydroxyurea to control hyperleukocytosis
  • Non-pregnant and non-nursing. Women of child-bearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (WOCBP is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 months).
  • Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for three months after the last dose of therapy.
  • Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control.
  • Men must agree not to father a child and must use a latex condom during any sexual contact with WOCBP while receiving therapy and for three months after therapy is stopped, even if they have undergone successful vasectomy.
  • Signed written informed consent

Ausschlusskriterien

  • Prior treatment with palbociclib
  • Performance status > 2 according to WHO criteria
  • Organ insufficiency: creatinine > 1.5 x upper normal serum level; bilirubin, AST, or AP > 2.5 x upper normal serum level; heart failure NYHA III/IV; uncontrolled hypertension; unstable angina; serious cardiac arrhythmia; severe obstructive or restrictive ventilation disorder
  • Uncontrolled infection
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
  • Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
  • Known or suspected active alcohol or drug abuse
  • Known positivity for HIV, active HAV, HBV, or HCV infection
  • Bleeding disorder unrelated to leukemia
  • Uncontrolled CNS involvement (treatment for CNS-involvement prior to inclusion is allowed)
  • QTc > 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
  • Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
  • No consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation
  • No consent for biobanking

Therapie

Intervention

Alle Patienten erhalten täglich Palbociclib oral.

Substanz

Sonstiges

Zuständige Gesamtstudie

Sponsor

Universitätsklinikum Ulm AÖR

Leiter der klinischen Prüfung (LKP)

Prof. Dr. Richard F. Schlenk

Studiengruppen/-zentrale

Study AML Group Ulm
0731/500-45911/
0731-500-45915
aml.sekretariat@uniklinik-ulm.de

Kontakt Klinische Studien

CIO Aachen: Uniklinik RWTH Aachen, +49 (0) 241 80-85490

CIO Bonn: Uniklinik Bonn, +49 (0) 228 287-16036

CIO Köln: Uniklinik Köln, +49 (0) 221 478-0

CIO Düsseldorf: Uniklinik Düsseldorf, +49 (0) 211 81-04150 (Mo-Do)